More importantly, studies have shown that not only does sGC inhibitor treatment suppress tumor growth and proliferation in TMPRSS2-ERG-positive PCa xerographs, but that it can also act strategically with an AR antagonist such as enzalutamide [90]. The gene discussed is ERG; the disease is neoplasm.